Literature DB >> 21728070

The PCa Tumor Microenvironment.

Joseph L Sottnik1, Jian Zhang, Jill A Macoska, Evan T Keller.   

Abstract

The tumor microenvironment (TME) is a very complex niche that consists of multiple cell types, supportive matrix and soluble factors. Cells in the TME consist of both host cells that are present at tumor site at the onset of tumor growth and cells that are recruited in either response to tumor- or host-derived factors. PCa (PCa) thrives on crosstalk between tumor cells and the TME. Crosstalk results in an orchestrated evolution of both the tumor and microenvironment as the tumor progresses. The TME reacts to PCa-produced soluble factors as well as direct interaction with PCa cells. In return, the TME produces soluble factors, structural support and direct contact interactions that influence the establishment and progression of PCa. In this review, we focus on the host side of the equation to provide a foundation for understanding how different aspects of the TME contribute to PCa progression. We discuss immune effector cells, specialized niches, such as the vascular and bone marrow, and several key protein factors that mediate host effects on PCa. This discussion highlights the concept that the TME offers a potentially very fertile target for PCa therapy.

Entities:  

Year:  2011        PMID: 21728070      PMCID: PMC3234329          DOI: 10.1007/s12307-011-0073-8

Source DB:  PubMed          Journal:  Cancer Microenviron        ISSN: 1875-2284


  171 in total

1.  Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer.

Authors:  Tanya B Dorff; Bryan Goldman; Jacek K Pinski; Philip C Mack; Primo N Lara; Peter J Van Veldhuizen; David I Quinn; Nicholas J Vogelzang; Ian M Thompson; Maha H A Hussain
Journal:  Clin Cancer Res       Date:  2010-05-18       Impact factor: 12.531

2.  Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants.

Authors:  H Gille; J Kowalski; B Li; J LeCouter; B Moffat; T F Zioncheck; N Pelletier; N Ferrara
Journal:  J Biol Chem       Date:  2000-10-31       Impact factor: 5.157

3.  Anti-interleukin-6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice.

Authors:  P C Smith; E T Keller
Journal:  Prostate       Date:  2001-06-15       Impact factor: 4.104

4.  Macrophages induce neuroendocrine differentiation of prostate cancer cells via BMP6-IL6 Loop.

Authors:  Geun Taek Lee; Seok Joo Kwon; Jae-Ho Lee; Seong Soo Jeon; Kee Taek Jang; Han Yong Choi; Hyun Moo Lee; Wun-Jae Kim; Dong Hyeon Lee; Isaac Yi Kim
Journal:  Prostate       Date:  2011-03-03       Impact factor: 4.104

5.  Endothelial progenitor cells and circulating endothelial cells in early prostate cancer: a comparison with plasma vascular markers.

Authors:  Andrew D Blann; Balu Balakrishnan; Eduard Shantsila; Peter Ryan; Gregory Y H Lip
Journal:  Prostate       Date:  2010-12-28       Impact factor: 4.104

Review 6.  Horizon scanning for novel therapeutics for the treatment of prostate cancer.

Authors:  D Bianchini; A Zivi; S Sandhu; J S de Bono
Journal:  Ann Oncol       Date:  2010-10       Impact factor: 32.976

7.  Differential expression of angiogenesis associated genes in prostate cancer bone, liver and lymph node metastases.

Authors:  Colm Morrissey; Lawrence D True; Martine P Roudier; Ilsa M Coleman; Sarah Hawley; Peter S Nelson; Roger Coleman; Ya-Chun Wang; Eva Corey; Paul H Lange; Celestia S Higano; Robert L Vessella
Journal:  Clin Exp Metastasis       Date:  2007-10-31       Impact factor: 5.150

Review 8.  The role of Dickkopf-1 in bone development, homeostasis, and disease.

Authors:  Joseph J Pinzone; Brett M Hall; Nanda K Thudi; Martin Vonau; Ya-Wei Qiang; Thomas J Rosol; John D Shaughnessy
Journal:  Blood       Date:  2008-08-07       Impact factor: 22.113

Review 9.  Role of endothelin-1 in osteoblastic bone metastases.

Authors:  Theresa A Guise; Juan Juan Yin; Khalid S Mohammad
Journal:  Cancer       Date:  2003-02-01       Impact factor: 6.860

10.  Host-derived RANKL is responsible for osteolysis in a C4-2 human prostate cancer xenograft model of experimental bone metastases.

Authors:  Colm Morrissey; Paul L Kostenuik; Lisha G Brown; Robert L Vessella; Eva Corey
Journal:  BMC Cancer       Date:  2007-08-03       Impact factor: 4.430

View more
  8 in total

Review 1.  Cancer immunotherapy: a paradigm shift for prostate cancer treatment.

Authors:  Dev Karan; Jeffrey M Holzbeierlein; Peter Van Veldhuizen; J Brantley Thrasher
Journal:  Nat Rev Urol       Date:  2012-05-29       Impact factor: 14.432

Review 2.  Recent advances in bone-targeted therapies of metastatic prostate cancer.

Authors:  Xiyun Deng; Guangchun He; Junwen Liu; Feijun Luo; Xiaoning Peng; Shigang Tang; Zhiyong Gao; Qinlu Lin; Jill M Keller; Tao Yang; Evan T Keller
Journal:  Cancer Treat Rev       Date:  2014-04-16       Impact factor: 12.111

3.  TLR9-Targeted STAT3 Silencing Abrogates Immunosuppressive Activity of Myeloid-Derived Suppressor Cells from Prostate Cancer Patients.

Authors:  Dewan M S Hossain; Sumanta K Pal; Dayson Moreira; Priyanka Duttagupta; Qifang Zhang; Haejung Won; Jeremy Jones; Massimo D'Apuzzo; Stephen Forman; Marcin Kortylewski
Journal:  Clin Cancer Res       Date:  2015-05-12       Impact factor: 12.531

4.  Prediction of treatment efficacy for prostate cancer using a mathematical model.

Authors:  Huiming Peng; Weiling Zhao; Hua Tan; Zhiwei Ji; Jingsong Li; King Li; Xiaobo Zhou
Journal:  Sci Rep       Date:  2016-02-12       Impact factor: 4.379

5.  Association between genetic polymorphisms of MMP8 and the risk of steroid-induced osteonecrosis of the femoral head in the population of northern China.

Authors:  Jieli Du; Tianbo Jin; Yuju Cao; Junyu Chen; Yongchang Guo; Mingqi Sun; Jian Li; Xiyang Zhang; Guoqiang Wang; Jianzhong Wang
Journal:  Medicine (Baltimore)       Date:  2016-09       Impact factor: 1.889

6.  The bone microenvironment promotes tumor growth and tissue perfusion compared with striated muscle in a preclinical model of prostate cancer in vivo.

Authors:  Haider Mussawy; Lennart Viezens; Malte Schroeder; Svenja Hettenhausen; Jördis Sündermann; Jasmin Wellbrock; Kai Kossow; Christian Schaefer
Journal:  BMC Cancer       Date:  2018-10-16       Impact factor: 4.430

7.  Regulation of epithelial plasticity by miR-424 and miR-200 in a new prostate cancer metastasis model.

Authors:  Jacqueline Banyard; Ivy Chung; Arianne M Wilson; Guillaume Vetter; Antony Le Béchec; Diane R Bielenberg; Bruce R Zetter
Journal:  Sci Rep       Date:  2013-11-06       Impact factor: 4.379

8.  Identification of genes regulating migration and invasion using a new model of metastatic prostate cancer.

Authors:  Jacqueline Banyard; Ivy Chung; Matthew Migliozzi; Derek T Phan; Arianne M Wilson; Bruce R Zetter; Diane R Bielenberg
Journal:  BMC Cancer       Date:  2014-05-30       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.